The risk and determinants of HCC in patients with primary biliary cholangitis (PBC) are unclear. We conducted a systematic review and meta-analysis of the incidence of HCC and risk factors associated with HCC risk among patients with PBC.
We searched PubMed, EMBASE, MEDLINE, Cochrane databases and reference lists from relevant articles to identify cohort studies that examined incidence of HCC in patients with PBC from inception through November 2019.
A total of 29 studies including 22,615 patients met the eligibility criteria. The median cohort size was 292 patients followed for an average of 76 months. The pooled incidence rate for patients with PBC was 4.17 per 1000 patient-years (95% CI 3.17–5.47). On subgroup analysis, the incidence of HCC in patients with PBC cirrhosis was 15.7 per 1000 patient-years (95% CI 8.73–28.24). The HCC incidence rate was 9.82 per 1000 person-years (95% CI 5.92–16.28) in men and 3.82 per 1000 person-years (95% CI 2.85–5.11) in women.
Cirrhosis is the strongest risk factor for HCC in patients with PBC. Male gender was also a risk factor. Our meta-analysis supports current recommendations of HCC surveillance in patients with PBC cirrhosis. Further studies are needed to evaluate risk factors in this population.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
Tax calculation will be finalised during checkout.
Primary biliary cirrhosis
Lindor KD, et al. Primary biliary cirrhosis. Hepatology. 2009;50:291–308.
Huet P-M, et al. Portal hypertension and primary biliary cirrhosis: effect of long-term ursodeoxycholic acid treatment. Gastroenterology. 2008;135:1552–1560.
Liang Y, Yang Z, Zhong R. Primary biliary cirrhosis and cancer risk: a systematic review and meta-analysis. Hepatology. 2012;56:1409–1417.
Boonstra K, et al. Increased cancer risk in a large population-based cohort of patients with primary biliary cirrhosis: follow-up for up to 36 years. Hepatol Int. 2014;8:266–274.
Kim KA, et al. Population-based epidemiology of primary biliary cirrhosis in South Korea. Aliment Pharmacol Ther. 2016;43:154–162.
Chen CT, et al. Increased risks of spontaneous bacterial peritonitis and interstitial lung disease in primary biliary cirrhosis patients with concomitant sjögren syndrome. Medicine (Baltimore). 2016;95:e2537.
Jones DEJ, Metcalf JV, Collier JD, Bassendine MF, James OFW. Hepatocellular carcinoma in primary biliary cirrhosis and its impact on outcomes. Hepatology. 1997;26:1138–1142.
Harada K, et al. Incidence of and risk factors for hepatocellular carcinoma in primary biliary cirrhosis: national data from Japan. Hepatology. 2013;57:1942–1949.
Trivedi PJ, et al. Stratification of hepatocellular carcinoma risk in primary biliary cirrhosis: a multicentre international study. Gut. 2016;65:321–329.
Shamseer L, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 2015;350:g7647.
Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–560.
Sutton AJ, Abrams KR, Jones DR, et al. Methods for meta-analysis in medical research. New York: Wiley; 2002.
Caballería L, et al. Hepatocellular carcinoma in primary biliary cirrhosis: similar incidence to that in hepatitis C virus-related cirrhosis. Am J Gastroenterol. 2001;96:1160–1163.
Floreani A, et al. Hepatic and extrahepatic malignancies in primary biliary cirrhosis. Hepatology. 1999;29:1425–1428.
Cavazza A, et al. Incidence, risk factors, and survival of hepatocellular carcinoma in primary biliary cirrhosis: comparative analysis from two centers. Hepatology. 2009;50:1162–1168.
Floreani A, et al. A 35-year follow-up of a large cohort of patients with primary biliary cirrhosis seen at a single centre. Liver Int. 2011;31:361–368.
Farinati F, et al. Hepatocellular carcinoma in primary biliary cirrhosis. J Hepatol. 1994;21:315–316.
Floreani A, et al. Incidence of hepatic and extra-hepatic malignancies in primary biliary cirrhosis (PBC). Ital J Gastroenterol. 1993;25:473–476.
Battezzati PM, et al. Ten-year combination treatment with colchicine and ursodeoxycholic acid for primary biliary cirrhosis: a double-blind, placebo-controlled trial on symptomatic patients. Aliment Pharmacol Ther. 2001;15:1427–1434.
Tomiyama Y, et al. Risk factors for survival and the development of hepatocellular carcinoma in patients with primary biliary cirrhosis. Intern Med. 2013;52:1553–1559.
Shibuya A, et al. Hepatocellular carcinoma and survival in patients with primary biliary cirrhosis. Hepatology. 2002;35:1172–1178.
Nakamura M, et al. Anti-gp210 and anti-centromere antibodies are different risk factors for the progression of primary biliary cirrhosis. Hepatology. 2007;45:118–127.
Jackson H, et al. Influence of ursodeoxycholic acid on the mortality and malignancy associated with primary biliary cirrhosis: a population-based cohort study. Hepatology. 2007;46:1131–1137.
Kuiper EMM, et al. Relatively high risk for hepatocellular carcinoma in patients with primary biliary cirrhosis not responding to ursodeoxycholic acid. Eur J Gastroenterol Hepatol. 2010;22:1495–1502.
Deutsch M, Papatheodoridis GV, Tzakou A, Hadziyannis SJ. Risk of hepatocellular carcinoma and extrahepatic malignancies in primary biliary cirrhosis. Eur J Gastroenterol Hepatol. 2008;20:5–9.
Findor J, He X-S, Sord J, Terg R, Gershwin ME. Primary biliary cirrhosis and hepatocellular carcinoma. Autoimmun Rev. 2002;1:220–225.
Ngu JH, Gearry RB, Frampton CM, Stedman CAM. Mortality and the risk of malignancy in autoimmune liver diseases: a population-based study in Canterbury. N Z Hepatol. 2012;55:522–529.
Gatselis NK, et al. Factors associated with progression and outcomes of early stage primary biliary cholangitis. Clin Gastroenterol Hepatol. 2020;18:684–692.e6.
Blachar A, Federle MP, Brancatelli G. Primary biliary cirrhosis: clinical, pathologic, and helical CT findings in 53 patients. Radiology. 2001;220:329–336.
Tana MM, et al. The significance of autoantibody changes over time in primary biliary cirrhosis. Am J Clin Pathol. 2015;144:601–606.
Chen C, Tseng Y, Yang C, Lin H. Increased risks of spontaneous bacterial peritonitis and interstitial lung disease in primary biliary cirrhosis patients with concomitant sjogren syndrome. Medicine. 2016;95:1–7.
Wong GLH, et al. A retrospective study on clinical features and prognostic factors of biopsy-proven primary biliary cirrhosis in Chinese patients. Am J Gastroenterol. 2005;100:2205–2211.
Wolke AM, Schaffner F, Kapelman B, Sacks HS. Malignancy in primary biliary cirrhosis. High incidence of breast cancer in affected women. Am J Med. 1984;76:1075–1078.
Zhang XX, et al. Primary biliary cirrhosis-associated hepatocellular carcinoma in Chinese patients: incidence and risk factors. World J Gastroenterol. 2015;21:3554–3563.
Rong G, et al. Incidence and risk factors for hepatocellular carcinoma in primary biliary cirrhosis. Clin Rev Allergy Immunol. 2015;48:132–141.
Lööf L, et al. Cancer risk in primary biliary cirrhosis: a population-based study from Sweden. Hepatology. 1994;20:101–104.
Cheung K-S, Seto W-K, Fung J, Lai C-L, Yuen M-F. Prognostic factors for transplant-free survival and validation of prognostic models in chinese patients with primary biliary cholangitis receiving ursodeoxycholic acid. Clin Transl Gastroenterol. 2017;8:e100.
Cheung K-S, Seto W-K, Fung J, Lai C-L, Yuen M-F. Epidemiology and natural history of primary biliary cholangitis in the chinese: a territory-based study in Hong Kong between 2000 and 2015. Clin Transl Gastroenterol. 2017;8:e116.
Gatselis NK, et al. Geoepidemiology, clinical manifestations and outcome of primary biliary cholangitis in Greece. Eur J Intern Med. 2017;42:81–88.
Hosonuma K, et al. Incidence, mortality, and predictive factors of hepatocellular carcinoma in primary biliary cirrhosis. Gastroenterol Res Pract. 2013;2013:168012.
Caturelli E, et al. Coarse nodular US pattern in hepatic cirrhosis: risk for hepatocellular carcinoma. Radiology. 2003;226:691–697.
Su CW, et al. Natural history and prognostic factors of primary biliary cirrhosis in Taiwan: a follow-up study up to 18 years. Liver Int. 2008;28:1305–1313.
Findor J, He X, Sord J, Terg R, Gershwin ME. Primary biliary cirrhosis and hepatocellular carcinoma. Autoim Rev. 2002;1:220–225.
Lin OS, Keeffe EB, Sanders GD, Owens DK. Cost-effectiveness of screening for hepatocellular carcinoma in patients with cirrhosis due to chronic hepatitis C. Aliment Pharmacol Ther. 2004;19:1159–1172.
Arguedas MR, Chen VK, Eloubeidi MA, Fallon MB. Screening for hepatocellular carcinoma in patients with hepatitis C cirrhosis: a cost-utility analysis. Am J Gastroenterol. 2003;98:679–690.
Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology. 2004;127:S35–S50.
Papatheodoridis GV, Chan HLY, Hansen BE, Janssen HLA, Lampertico P. Risk of hepatocellular carcinoma in chronic hepatitis B: assessment and modification with current antiviral therapy. J Hepatol. 2015;62:956–967.
Tansel A, et al. Incidence and determinants of hepatocellular carcinoma in autoimmune hepatitis: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2017;15:1207–1217.e4.
Wong RJ, Gish R, Frederick T, Bzowej N, Frenette C. Development of hepatocellular carcinoma in autoimmune hepatitis patients: a case series. Dig Dis Sci. 2011;56:578–585. https://doi.org/10.1007/s10620-010-1444-6.
Teufel A, et al. Hepatocellular carcinoma in patients with autoimmune hepatitis. World J Gastroenterol. 2009;15:578–582.
Sarasin FP, Giostra E, Hadengue A. Cost-effectiveness of screening for detection of small hepatocellular carcinoma in western patients with child-pugh class A cirrhosis. Am J Med. 1996;101:422–434.
This research was not funded. Dr Kanwal receives funding from in part by the U.S. Department of Veterans Affairs, and the Houston Veterans Affairs Health Services Research Center of Innovations (CIN13-413).
Conflict of interest
The authors declare no conflict of interest. The views expressed in this article are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs or the National Institute of Diabetes Digestive and Kidney Diseases.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Electronic Supplementary Material
Below is the link to the electronic supplementary material.
“liver cirrhosis, biliary”[mesh: noexp]
“primary biliary cirrhosis” [TIAB]
“primary biliary cholangitis” [TIAB]
#1 OR #2 OR #3
(liver[TIAB] OR hepatocellular[TIAB])
(carcinoma[TIAB] OR cancer*[TIAB] OR neoplasm*[TIAB] OR malignancy[tiab])
#5 AND #6
liver neoplasms [mesh: noexp]
#7 OR #8
#4 AND #9
About this article
Cite this article
Natarajan, Y., Tansel, A., Patel, P. et al. Incidence of Hepatocellular Carcinoma in Primary Biliary Cholangitis: A Systematic Review and Meta-Analysis. Dig Dis Sci (2020). https://doi.org/10.1007/s10620-020-06498-7
- Hepatocellular carcinoma
- Primary biliary cirrhosis
- Risk factor
- Natural history
- Systematic review